Matthew Scholz

Matthew Scholz is a seasoned executive with extensive experience in biotechnology and technology management. Currently serving as CEO and founder of Oisin Biotechnologies since February 2014, Scholz leads efforts in developing therapeutics targeting senescent and cancerous cells. As CEO of OncoSenX and Co-Founder and Chief Technical Officer of Aegis Life, Inc., Scholz contributes to innovative approaches in the biotech field. Additionally, Scholz has held multiple leadership roles at Immusoft Corporation, where growth and partnerships with significant investors and research centers have been achieved. As a Co-Founder of Sigma Genetics, Inc., Scholz is involved in advancing DNA delivery technologies, while previous experience includes founding and managing Point B Telematics, focusing on fleet logistics optimization. Scholz's educational background includes a BS in Computer Science from the University of Washington and participation in Y Combinator.